Age-Related Macular Degeneration (AMD) is a progressive disease that damages the macula, the part of the retina responsible for sharp, central vision. Several treatments exist, including intravitreal injections of anti-vascular endothelial growth factor (VEGF) drugs like Lucentis and Avastin, laser photocoagulation, and photodynamic therapy with Verteporfin. These therapies aim to slow or halt the progression of AMD and preserve vision. In some cases, surgery like a macular translocation or vitrectomy may be necessary.
Age-Related Macular Degeneration (AMD) is a progressive disease that damages the macula, the part of the retina responsible for sharp, central vision. Several treatments exist, including intravitreal injections of anti-vascular endothelial growth factor (VEGF) drugs like Lucentis and Avastin, laser photocoagulation, and photodynamic therapy with Verteporfin. These therapies aim to slow or halt the progression of AMD and preserve vision. In some cases, surgery like a macular translocation or vitrectomy may be necessary.
Age-Related Macular Degeneration (AMD) treatment in the US often involves intravitreal injections of anti-VEGF medications like Lucentis or Eylea, which help slow down the progression of the disease. Regular monitoring is necessary.
The US has some of the world's most advanced AMD treatments but comes with high costs. Patients may pay out-of-pocket or use insurance. Injections can cost $1,000-$2,500 per session, with multiple sessions needed annually.